Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Dose-Escalation and Efficacy/Safety Study of Afuresertib Plus Sintilimab Plus Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 Treatment

Next Previous
X
Search
Trial Profile

A Phase I/II Dose-Escalation and Efficacy/Safety Study of Afuresertib Plus Sintilimab Plus Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 Treatment

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afuresertib (Primary) ; Docetaxel (Primary) ; Paclitaxel (Primary) ; Sintilimab (Primary)
  • Indications Adenosquamous carcinoma; Carcinoma; Cervical cancer; Endometrial cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Laekna Therapeutics

    • Most Recent Events

    • 25 Aug 2023 According to a Laekna, Inc. media release, company has completed three out of four cohorts of the dose escalation study and have observed high response rate in cervical cancer (CC) and endometrial cancer (EC) patients who have been treated up to 3 lines of SOCs including PD-1 drugs and/or chemotherpy.
    • 22 Aug 2023 Planned primary completion date changed from 31 Aug 2023 to 31 Aug 2024.
    • 31 Jul 2022 According to an Innovent Biologics media release, first patient of cervical cancer has been dosed in this Phase 1/2 clinical trial, The study is planned to be extended as a multi-regional clinical trial at the pivotal stage.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top